Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).

Author: BullingerLars, CalandraThierry, Garcia-VidalCarolina, HerbrechtRaoul, MaertensJohan, MaschmeyerGeorg, MennaPierantonio, PaganoLivio, Thiebaut-BertrandAnne

Overview

This conference reviewed the infectious complications and febrile neutropenia associated with novel immunotherapeutic and molecular targeted drugs for acute myeloid and lymphoblastic leukemia. While most agents were safe as monotherapy, caution is recommended with combination therapies involving venetoclax, gemtuzumab ozogamicin, or midostaurin. Evidence-based recommendations for infection prevention and management were developed.

Paper Details　

Original Abstract of the Article :

The 9th web-based European Conference on Infections in Leukemia (ECIL-9), held September 16-17, 2021, reviewed the risk of infections and febrile neutropenia associated with more recently approved immunotherapeutic agents and molecular targeted drugs for the treatment of acute myeloid leukemia (AML)...See full text at original site

Dr.Camel's Paper Summary Blog

Navigating the Complex Landscape of Infections in Acute Leukemia

Acute leukemia is a serious blood cancer that can severely weaken the immune system, leaving patients vulnerable to infections, like a desert traveler exposed to the elements. This study examines the risk of infections associated with targeted drugs and biotherapies used to treat acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The researchers explored the potential for these therapies to increase susceptibility to infections and identified strategies to minimize these risks.

A Careful Journey Through the Desert of Cancer Treatment

The study provides guidance on managing infectious complications associated with targeted therapies for acute leukemia. While many of these therapies are not associated with a significant increase in infection risk when used alone, the study emphasizes the importance of careful monitoring and preventive measures, particularly when these therapies are combined with other treatments. The researchers, like experienced desert guides, are navigating the complex and potentially hazardous terrain of cancer treatment.

Protecting Patients in the Desert of Cancer Treatment

This research provides valuable insights for healthcare providers treating patients with acute leukemia. The study highlights the importance of individualized approaches to infection prevention and management, ensuring that patients receive the best possible care during treatment. It is crucial to work closely with your healthcare team to understand the potential risks and benefits of your specific treatment plan.

Dr.Camel's Conclusion

This research underscores the importance of careful monitoring and preventive measures to minimize the risk of infections in patients receiving targeted therapies for acute leukemia. Like a skilled desert navigator, healthcare professionals must anticipate potential challenges and be prepared to adapt treatment strategies to ensure patient safety and well-being.